ESMO 2021

Adjuvant pembrolizumab prolongs relapse-free survival, when compared with placebo, in patients with resected, stage II melanoma.

The addition of nivolumab to chemotherapy demonstrated continuing improved survival compared with chemotherapy alone after 24 months of follow-up.

Updated results from the phase 3 CASPIAN study further established first-line durvalumab with platinum-etoposide as a standard of care for ES-SCLC.

The median PFS was 8.0 months with TARE and 7.2 months with chemotherapy alone.

Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.

SYD985 may provide a new treatment option for patients with previously treated locally advanced or metastatic HER2-positive metastatic breast cancer.

Sugemalimab improved progression-free survival whether patients received sequential or concurrent chemoradiotherapy.

The overall survival benefit with ribociclib increased over time.

At data cutoff, 562 of 626 patients enrolled in the study were eligible for primary endpoint assessment.

Dose-dense methotrexate plus vinblastine, doxorubicin, and cisplatin improved time to progression.